|
1
|
Jelovac D and Armstrong DK: Role of
farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des.
18:3812–3815. 2012.
|
|
2
|
Wang Y, Yu Y, Tsuyada A, Ren X, Wu X,
Stubblefield K, Rankin-Gee EK and Wang SE: Transforming growth
factor-β regulates the sphere-initiating stem cell-like feature in
breast cancer through miRNA-181 and ATM. Oncogene. 30:1470–1480.
2011.
|
|
3
|
Bhola NE, Balko JM, Dugger TC, Kuba MG,
Sanchez V, Sanders M, Stanford J, Cook RS and Arteaga CL: TGF-β
inhibition enhances chemotherapy action against triple-negative
breast cancer. J Clin Invest. 123:1348–1358. 2013.
|
|
4
|
Somervaille TC, Matheny CJ, Spencer GJ,
Iwasaki M, Rinn JL, Witten DM, Chang HY, Shurtleff SA, Downing JR
and Cleary ML: Hierarchical maintenance of MLL myeloid leukemia
stem cells employs a transcriptional program shared with embryonic
rather than adult stem cells. Cell Stem Cell. 4:129–140. 2009.
|
|
5
|
Achilleos A and Trainor PA: Neural crest
stem cells: discovery, properties and potential for therapy. Cell
Res. 22:288–304. 2012.
|
|
6
|
Huang FT, Zhuan-Sun YX, Zhuang YY, Wei SL,
Tang J, Chen WB and Zhang SN: Inhibition of hedgehog signaling
depresses self-renewal of pancreatic cancer stem cells and reverses
chemoresistance. Int J Oncol. 41:1707–1714. 2012.
|
|
7
|
Latifi A, Luwor RB, Bilandzic M,
Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA,
Findlay JK and Ahmed N: Isolation and characterization of tumor
cells from the ascites of ovarian cancer patients: molecular
phenotype of chemoresistant ovarian tumors. PLoS One.
7:e468582012.
|
|
8
|
Ponnusamy MP, Seshacharyulu P, Vaz A, Dey
P and Batra SK: MUC4 stabilizes HER2 expression and maintains the
cancer stem cell population in ovarian cancer cells. J Ovarian Res.
4:72011.
|
|
9
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007.
|
|
10
|
Wierstra I and Alves J: FOXM1, a typical
proliferation-associated transcription factor. Biol Chem.
388:1257–1274. 2007.
|
|
11
|
Gemenetzidis E, Elena-Costea D, Parkinson
EK, Waseem A, Wan H and Teh MT: Induction of human epithelial
stem/progenitor expansion by FOXM1. Cancer Res. 70:9515–9526.
2010.
|
|
12
|
Bao B, Wang Z, Ali S, Kong D, Banerjee S,
Ahmad A, Li Y, Azmi AS, Miele L and Sarkar FH: Over-expression of
FoxM1 leads to epithelial-mesenchymal transition and cancer stem
cell phenotype in pancreatic cancer cells. J Cell Biochem.
112:2296–2306. 2011.
|
|
13
|
Akiyama T, Ishida J, Nakagawa S, Ogawara
H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a
specific inhibitor of tyrosine-specific protein kinases. J Biol
Chem. 262:5592–5595. 1987.
|
|
14
|
Hillman GG, Wang Y, Kucuk O, Che M, Doerge
DR, Yudelev M, Joiner MC, Marples B, Forman JD and Sarkar FH:
Genistein potentiates inhibition of tumor growth by radiation in a
prostate cancer orthotopic model. Mol Cancer Ther. 3:1271–1279.
2004.
|
|
15
|
Barnes S: Effect of genistein on in vitro
and in vivo models of cancer. J Nutr. 125(3 Suppl): 777S–783S.
1995.
|
|
16
|
Wang Z, Ahmad A, Banerjee S, Azmi A, Kong
D, Li Y and Sarkar FH: FoxM1 is a novel target of a natural agent
in pancreatic cancer. Pharm Res. 27:1159–1168. 2010.
|
|
17
|
Ning Y, Li Q, Xiang H, Liu F and Cao J:
Apoptosis induced by 7-difluoromethoxyl-5,4′-di-n-octyl genistein
via the inactivation of FoxM1 in ovarian cancer cells. Oncol Rep.
27:1857–1864. 2012.
|
|
18
|
Xiang HL, Liu F, Quan MF, Cao JG and Lv Y:
7-difluoromethoxyl-5,4′-di-n-octylgenistein inhibits growth of
gastric cancer cells through downregulating forkhead box M1. World
J Gastroenterol. 18:4618–4626. 2012.
|
|
19
|
Reynolds BA and Weiss S: Clonal and
population analyses demonstrate that an EGF-responsive mammalian
embryonic CNS precursor is a stem cell. Dev Biol. 175:1–13.
1996.
|
|
20
|
Shi X, Gipp J and Bushman W:
Anchorage-independent culture maintains prostate stem cells. Dev
Biol. 312:396–406. 2007.
|
|
21
|
Zhang S, Balch C, Chan MW, Lai HC, Matei
D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and
characterization of ovarian cancer-initiating cells from primary
human tumors. Cancer Res. 68:4311–4320. 2008.
|
|
22
|
Van den Broeck A, Gremeaux L, Topal B and
Vankelecom H: Human pancreatic adenocarcinoma contains a side
population resistant to gemcitabine. BMC Cancer. 12:3542012.
|
|
23
|
Penumatsa K, Edassery SL, Barua A,
Bradaric MJ and Luborsky JL: Differential expression of aldehyde
dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian
tumors. J Ovarian Res. 3:282010.
|
|
24
|
Creighton CJ, Chang JC and Rosen JM:
Epithelial-mesenchymal transition (EMT) in tumor-initiating cells
and its clinical implications in breast cancer. J Mammary Gland
Biol Neoplasia. 15:253–260. 2010.
|
|
25
|
Wang Z, Ahmad A, Li Y, Banerjee S, Kong D
and Sarkar FH: Forkhead box M1 transcription factor: a novel target
for cancer therapy. Cancer Treat Rev. 36:151–156. 2010.
|
|
26
|
Wang Z, Li Y, Ahmad A, Banerjee S, Azmi
AS, Kong D, Wojewoda C, Miele L and Sarkar FH: Down-regulation of
Notch-1 is associated with Akt and FoxM1 in inducing cell growth
inhibition and apoptosis in prostate cancer cells. J Cell Biochem.
112:78–88. 2011.
|
